Neurodegenerative disorders: Clues from glutamate and energy metabolism

Critical Reviews in Neurobiology

Volumn 10, Issue 2, 1996, Pages 239-263

  Ikonomidou, Chrysanthy ^a   Turski, Lechoslaw ^b  

^a HUMBOLDT UNIVERSITY   (Germany)

^b BAYER PHARMA AG   (Germany)

Author keywords

Aging; Excitotoxicity; Huntington's disease; Ischemia; Mitochondrial toxins; Neurodegeneration; Parkinson's disease; Trauma

Indexed keywords

GANGLIOSIDE; GLUTAMATE RECEPTOR; GLUTAMIC ACID; N METHYL DEXTRO ASPARTIC ACID RECEPTOR;

AGING; BRAIN INJURY; BRAIN ISCHEMIA; CORPUS STRIATUM; ENERGY METABOLISM; HUMAN; HUNTINGTON CHOREA; MITOCHONDRIAL RESPIRATION; NERVE DEGENERATION; NEUROPATHOLOGY; NEUROTOXICITY; NONHUMAN; PARKINSON DISEASE; REVIEW; SUBSTANTIA NIGRA;

EID: 0030478699     PISSN: 08920915     EISSN: None     Source Type: Journal    
DOI: 10.1615/critrevneurobiol.v10.i2.50     Document Type: Review

References (301)

1. Hayashi, T., A physiological study of epileptic seizures following cortical stimulation in animals and its application to human clinics, Jpn. J. Pharmacol., 3. 46, 1952.
2. Hayashi, T., Inhibition and excitation due to γ-aminobutyric acid in the central nervous system, Nature, 182, 1076, 1958.
3. Lucas, D. R. and Newhouse, J. P., The toxic effect of sodium L-glutamate on the inner layers of the retina, Arch. Ophthalmol., 58, 193, 1957.
4. Olney, J. W., Brain lesions, obesity and other disturbances in mice treated with monosodium glutamate, Science, 164, 719, 1969.
5. Olney, J. W. and Sharpe, L. G., Brain lesions in infant rhesus monkey treated with monosodium glutamate, Science, 166, 386, 1969.
6. Rothman, S. M., Synaptic activity mediates death of hypoxic neurons, Science, 220, 536, 1983.
7. Choi, D. W., Ionic dependence of glutamate neurotoxicity in cortical cell culture, J. Neurosci., 7, 369, 1987.
8. Watkins, J. C., Thirty years of excitatory amino acid research, in Frontiers in Excitatory Amino Acid Research, Cavalheiro, E. A., Lehmann, J., and Turski, L., Eds., Liss, New York, 1988, 3.
9. Croucher, M. J., Collins, J. F., and Meldrum, B. S., Anticonvulsant action of excitatory amino acid antagonists, Science, 216, 899, 1992.
10. Turski, L., Schwarz, M., Turski, W. A., Klockgether, T., and Sontag, K.-H., Muscle relaxant action of excitatory amino acid antagonists, Neurosci. Lett., 53, 321, 1985.
11. Stephens, D. N., Meldrum, B. S., Weidmann, R., Schneider, C., and Grützner, M., Does the excitatory amino acid receptor antagonist 2-APH exhibit anxiolytic activity? Psychopharmacology, 85, 143, 1996.
12. Simon, R. P., Swan, J. H., Griffith, T., and Meldrum, B. S., Blockade of N-methyl-D-aspartate receptors may protect against ischemic damage in the brain, Science, 226, 850, 1984.
13. Sandercock, P. and Willems, H., Medical treatment of acute ischemic stroke, Lancet, 339, 1540, 1992.
14. Donnan, G. A., Investigation of patients with stroke and transient ischaemic attacks, Lancet, 339, 473, 1992.
15. Adams, J. H., Head injury, in Greenfield's Neuropathology, Adams, J. H. and Duchen, L. W., Eds., Arnold, London, 1992, 106.
16. Pulsinelli, W., Pathophysiology of acute ischaemic stroke, Lancet, 339, 533, 1992.
17. Lipton, S. A., Molecular mechanisms of trauma-induced neuronal degeneration, Curr. Opinion Neurol. Neurosurg., 6, 588, 1993.
18. Benveniste, H., Drejer, J., Schousboe, A., and Diemer, N. H., Elevation of extracellular concentrations of glutamate and aspartate in rat hippocampus during transient cerebral ischemia monitored by intracerebral microdialysis, J. Neurochem., 43, 1369, 1984.
19. Globus, M. Y.-T., Busto, R., Dietrich, W. D., Martinez, E., Valdes, I., and Ginsberg, M. D., Effect of ischemia on the in vivo release of striatal dopamine, glutamate, and γ-aminobutyric acid studied by intracerebral microdialysis, J. Neurochem., 51, 1455, 1988.
20. Miyashita, K., Abe, H., Nakajima, T., Ishikawa, A., Nishiura-Suzuki, M., Naritomi, H., Tanaka, R., and Sawada, T., Glutamate release in the gerbil hippocampus after middle cerebral artery occlusion, Neuroreport, 5, 945, 1994.
21. Uchiyama-Tsuyuki, Y., Araki, H., Yae, T., and Otomo, S., Changes in the extracellular concentrations of amino acids in the rat striatum during transient focal cerebral ischemia, J. Neurochem., 62,1074, 1994.
22. Faden, A. I., Demediuk, P., Panter, S. S., and Vink, R., The role of excitatory amino acids and NMDA receptors in traumatic brain injury, Science, 244, 798, 1989.
23. Liu, D., Thangnipon, W., and McAdoo, D. J., Excitatory amino acids rise to toxic levels upon impact injury to the rat spinal cord, Brain Res., 547, 344, 1991.
24. Palmer, A. M., Marion, D. W., Botscheller, M. L., Swedlow, P. E., Styren, S. D., and DeKosky, S. T., Traumatic brain injury-induced excitotoxicity assessed in a controlled cortical impact model, J. Neurochem., 61, 2015, 1993.
25. Ottersen, O. P., Torp, R., and Meldrum, B. S., Glutamate neurotransmission during and after ischemia: histochemical studies, Neuropsychopharmacology, 10, S209, 1994.
26. Person, L. and Hillered, L., Chemical monitoring of neurosurgical intensive care patients using intracerebral microdialysis, J. Neurosurg., 76, 72, 1992.
27. Bondoli, A., Barbi, S., Camaioni, D., Della Morte, F., and Magalini, S. J., Plasma and cerebrospinal fluid free amino acid concentration in post-traumatic cerebral oedema in patients with shock, Resuscitation, 9, 119, 1981.
28. Baker, A. J., Moulton, R. J., MacMillan, V. H., and Shedden, P. M., Excitatory amino acids in cerebrospinal fluid following traumatic brain injury in humans, J. Neurosurg., 79, 369, 1993.
29. Pulsinelli, W., Sarokin, A., and Buchan, A., Antagonism of the NMDA and non-NMDA receptors in global versus focal brain ischemia, Prog. Brain Res., 96, 125, 1993.
30. Wahlstedt, C., Golanov, E., Yamamoto, S., Yee, F., Ericson, H., Yoo, H., Inturrisi, C. E., and Reis, D. J., Antisense oligodeoxynucleotides to NMDA-R1 receptor channel protect cortical neurons from excitotoxicity and reduce focal ischaemic infarctions, Nature, 363, 260, 1993.
31. Buchan, A., Do NMDA antagonists protect against cerebral ischemia: are clinical trials warranted? Cerebrovasc. Brain Metab. Rev., 2, 1, 1990.
32. Meldrum, B. S., Protection against ischemic neuronal damage by drugs acting on excitatory neurotransmission, Cerebrovasc. Brain Metab. Rev., 2, 27, 1990.
33. Hasegawa, Y., Fisher, M., Baron, B. M., and Metcalf, G., The competitive NMDA antagonist MDL-100,453 reduces infarct size after experimental stroke, Stroke, 25, 1241, 1994.
34. Foster, A. C., Gill, R., Woodruff, G. N., and Iversen, L. L., Non-competitive NMDA receptor antagonists and ischemia-induced neuronal degeneration, in Frontiers in Excitatory Amino Acid Research, Cavalheiro, E. A., Lehmann, J., and Turski, L., Eds., Liss, New York, 1988, 707.
35. Steinberg, G. K., Saleh, J., and Kunis, D., Delayed treatment with dextromethorphan and dextrorphan reduces cerebral damage after transient focal ischemia, Neurosci. Lett., 89, 193, 1988.
36. Bullock, R., McCulloch, J., Graham, D. I., Lowe, D., Chen, M. H., and Teasdale, G. M., Focal ischemic damage is reduced by CPP-ene, Stroke, 21, 111-32, 1990.
37. Peruche, B. and Kriegistein, J., Mechanisms of drug actions against neuronal damage caused by ischemia, Prog. Neuropsychopharmacol. Biol. Psychiat., 17, 21, 1992.
38. Park, C. K., McBurney, R. N., Holt, W. F., Cotter, R. E., McCulloch, J., Kang, J. K., and Choi, C. R., The dose-dependency of the antiischemic efficacy and of the side effects of a novel NMDA antagonist, CNS 1102, J. Cereb. Blood Flow Metab., 13, S641, 1993.
39. Nishikawa, T., Kirsch, J. R., Koehler, R. C., Miyabe, M., and Traystman, R. J., Competitive N-methyl-D-aspartate receptor blockade reduces brain injury following transient focal ischemia in cats, Stroke, 25, 2258, 1994.
40. Jensen, F. E., Edgecomb, P., Sondheimer, N., Lipton, S., and Stieg, P., Memantine is protective after stroke, has fewer behavioral side effects than MK-801, and does not block long-term potentiation, Ann. Neurol., 36, 304, 1994.
41. Warner, D. S., Martin, H., Ludwig, P., McAllister, A., Keana, J. F. W., and Weber, E., In vivo models of cerebral ischemia: effects of parenterally administered NMDA receptor glycine site antagonists, J. Cereb. Blood Flow Metab., 15, 188, 1995.
42. Gill, R., Hargreaves, R. J., and Kemp, J. A., The neuroprotective effect of the glycine site antagonist 3R-(+)-cis-4-methyl-HA966 (L-687-414) in a rat model of focal ischemia, J. Cereb. Blood Flow Metab., 15, 197, 1995.
43. Gotti, B., Duverger, D., Bertin, J., Carter, C., Dupont, R., Frost, J., Gaudiliiere, B., MacKenzie, E. T., Rousseau, J., Scatton, B., and Wick, A., Ifenprodil and SL 82.0715 as cerebral antiischemic agents. I. Evidence for efficacy in models of focal cerebral ischemia, J. Pharmacol. Exp. Ther., 247, 1211, 1988.
44. Gotti, B., Benavides, J., MacKenzie, E. T., and Scatton, B., The pharmacology of focal cortical ischaemia in the mouse, Brain Res., 522, 290, 1990.
45. Carter, C., Benavides, J., Dana, C., Schoemaker, H., Perrault, G., Sanger, D., and Scatton, B., Non-competitive NMDA receptor antagonists acting on the polyamine site, in Excitatory Amino Acid Antagonists, Meldrum, B. S., Ed., Blackwell, Oxford, 1991, 130.
46. 2+ channels in rat cultured cortical neurons, Eur. J. Pharmacol., 257, 297, 1994.
47. Lanier, W. L., Perkins, W. J., Karlsson, B. R., Milde, J. H., Scheithauer, B. W., Sherman, G. T., and Michenfelder, J. T., The effects of dizocilpine maleate (MK-801), an antagonist of the N-methyl-D-aspartate receptor, on ischemia in primates, J. Cereb. Blood Flow Metab., 10, 252, 1990.
48. Diemer, N. H., Jorgensen, M. B., Johansen, F. F., Sheardown, M., and Honore, T., Protection against ischemic hippocampal CA1 damage in the rat with a new non-NMDA antagonist, NBQX, Acta Neurol. Scand., 86, 45, 1993.
49. Lipton, S. A., Molecular mechanisms of trauma-induced neuronal degeneration, Curr. Opinion Neurol. Neurosurg., 6, 588, 1993.
50. Faden, A. I. and Simon, R. P., A potential role for excitotoxins in the pathophysiology of spinal cord injury, Ann. Neurol., 23, 623, 1988.
51. Inglis, F., Kuroda, Y., and Bullock, R., Glucose hypermetabolism after acute subdural hematoma is ameliorated by a competitive NMDA antagonist, J. Neurotrauma, 9, 75, 1992.
52. McIntosh, T., Soares, H., Hayes, R., and Simon, R., The NMDA receptor antagonist MK-801 prevents edema and restores magnesium homeostasis after traumatic brain injury in rats, in Frontiers in Excitatory Amino Acid Research, Cavalheiro, E. A., Lehmann, J., and Turski, L., Eds., Liss, New York, 1988, 653
53. Shapira, Y., Lam, A. M., Eng, C. C., Laohaprasit, V., and Michel, M., Therapeutic time window and dose response of the beneficial effects of ketamine in experimental head injury, Stroke, 25, 1637, 1994.
54. Smith, D. H., Okiyama, K., Thomas, M. J., and McIntosh, T. K., Effects of the excitatory amino acid receptor antagonists kynurenate and indole-2-carboxylic acid on behavioral and neurochemical outcome following experimental brain injury, J. Neurosci., 13, 5383, 1993.
55. Hicks, R. R., Smith, D. H., Gennarelli, T. A., and Mclntosh, T., Kynurenate is neuroprotective following experimental brain injury in the rat, Brain Res., 655, 91, 1994.
56. Toulmond, S., Serrano, A., Benavides, J., and Scatton, B., Prevention by eliprodil (SL 82.0715) of traumatic brain damage in the rat. Existence of a large (18 h) therapeutic window, Brain Res., 620, 32, 1993.
57. Bernert, H., Löschmann, P.-A., and Turski, L., NBQX protects rats against traumatic brain injury, Soc. Neurosci. Abstr., 18, 1087, 1992.
58. Olney, J. W., Labruyere, J., and Price, M. T., Pathological changes induced in cerebrocortical neurons by phencyclidine and related drugs, Science, 244, 1360, 1989.
59. Olney, J. W., Labruyere, J., Wang, G., Wozniak, D. F., Price, M. T., and Sesma, M. A., NMDA antagonist neurotoxicity: mechanism of prevention, Science, 254, 1515, 1991.
60. Fix, A. S., Long, G. G., Wozniak, D. F., and Olney, J. W., Pathomorphologic effects of N-methyl-D-aspartate antagonists in the rat posterior cingulate/ retrosplenial cerebral cortex: a review, Drug Dev. Res., 32,147, 1994.
61. Hargreaves, R. J., Rigby, M., Smith, D., and Hill, R. G., Lack of effect of L-687,414 ((+)-cis-4-methyl-HA-966), an NMDA receptor antagonist acting at the glycine site, on cerebral glucose metabolism and cortical neuronal morphology, Br. J. Pharmacol., 110, 36, 1993.
62. Berger, P., Farrel, K., Sharp, F., and Skolnick, P., Drugs acting at the strychnine-insensitive glycine receptor do not induce HSP-70 protein in the cingulate cortex, Neurosci. Lett., 168, 147, 1994.
63. Duval, D., Roome, N., Gauffeny, C., Nowicki, J. P., and Scatton, B., SL 82.0715, an NMDA antagonist acting at the polyamine site, does not induce neurotoxic effects on rat cortical neurons, Neurosci. Lett., 137, 193, 1992.
64. Foutz, A. S., Champagnat, J., and Denavit-Saubrie, M., N-methyl-D-aspartate (NMDA) receptors control respiratory off-switch in cat, Neurosci. Lett, 87, 221, 1988.
65. Pierrefiche, O., Foutz, A. S., and Denavit-Saubrie, M., Pneumotaxic mechanisms in the nonhuman primate: effect of the N-methyl-D-aspartate (NMDA) antagonist ketamine, Neurosci. Lett., 119, 90, 1990.
66. Scheller, M. S., Zornow, M. H., Fleischer, J. E., Sherman, G. T., and Gerber, T. F., The noncompetitive N-methyl-D-aspartate receptor antagonist, MK-801 profoundly reduces volatile anesthetic requirements in rabbits, Neuropharmacology, 28, 677, 1989.
67. Daniell, L.C., Effect of CGS 19755, a competitive N-methyl-D-aspartate antagonist, on general anesthetic potency, Pharmacol. Biochem. Behav., 40, 767, 1991.
68. Danilevich, E. J., Galtseva, I. V., Kuznetsowa, O. J., Lapshin, V. N., and Michailovich, V. A., The influence of ketamine anesthesia given to patients with critical trauma at the prehospital stage upon the course of outcome of shock, Vest. Khir., 145, 104, 1990.
69. Belyakov, V. A., Sinitsyn, L. N., Maksimov, G. A., Akulov, M. S., Kalachyov, S. A., and Medvedsky, A. N., Analgesia and anesthesia in patients with mechanical traumas at prehaspital stage, Anesth. Reanimatol., 5, 24, 1993.
70. Grotta, J., Safety and tolerability of the glutamate antagonist CGS19755 in acute stroke patients, Stroke, 25, 255, 1994.
71. Clark, W. M. and Coull, B. M., Randomized trial of CGS19755, a glutamate antagonist, in acute ischemic stroke treatment, Neurology, 44, A270, 1994.
72. Herrling, P. L., D-CPPene (SDZ EAA 494), a competitive NMDA antagonist: results from animal models and first results in humans, Neuropsychopharmacology, 10, S591, 1994.
73. Fisher, M., Cerestat™ (CNS 1102), a noncompetitive NMDA antagonist, in ischemic stroke patients: dose-escalating safety study, Cardiovasc. Dis., 4, 245, 1994.
74. Gamzu, E. R. and McBurney, R., Cerestat™ (CNS1102) - preliminary results in stroke and TBI patients, Neuropsychopharmacology, 10, S592, 1994.
75. Albers, G. W., Atkinson, R., Kelley, R., and Rosenbaum, D. M., Safety, tolerability, and pharmacokinetics of the N-methyl-D-aspartate antagonist dextrorphan in patients with acute stroke, Stroke, 26, 254, 1995.
76. Giroux, C., Garreau, M., and Morselli, P. L., Glutamate receptor antagonists in stroke patients, Neuropsychopharmacology, 10, S213, 1994.
77. Buchan, A. M., Xue, D., Huang, Z. G., Smith, K. H., and Lesiuk, H., Delayed AMPA receptor blockade reduces cerebral infarction induced by focal ischemia, Neuroreport, 2, 473, 1991.
78. Gill, R., Nordholm, L., and Lodge, D., The neuroprotective actions of 2,3-dihydroxy-6-nitro-7-sulfamoyl-benzo(F)quinoxaline (NBQX) in a rat focal ischemia model, Brain Res., 580, 35, 1992.
79. Smith, S. and Meldrum, B. S., Cerebroprotective effect of a non-N-methyl-D-aspartate antagonist, GYKI 52466, after focal ischemia in the rat, Stroke, 23, 861, 1992.
80. Shimizu-Sasamata, M., Kawasaki, S., Yatsugi, S., Ohmori, J., Sakamoto, S., Koshiyk, K, Usuda, S., and Murase, K., The neuroprotective action of YM900, a novel and potent AMPA receptor antagonist, in a rat focal ischemia model, J. Cereb. Blood Flow Metab., 13, S664, 1993.
81. Bullock, R., Graham, D. I., Swanson, S., and McCulloch, J., Neuroprotective effect of the AMPA receptor antagonist LY-293558 in focal cerebral ischemia in the cat, J. Cereb. Blood Flow Metab., 14, 466, 1994.
82. Xue, D., Huang, Z.-G., Barnes, K-, Lesiuk, H. J., Smith, K. E., and Buchan, A. M., Delayed treatment with AMPA, but not NMDA, antagonists reduces neocortical infarction, J. Cereb. Blood Flow Metab., 14, 251, 1994.
83. Gill, R. and Lodge, D., The neuroprotective effects of the decahydroisoquinoline, LY215490; novel AMPA antagonist in focal ischaemia, Neuropharmacology, 33, 1529, 1994.
84. Meden, P., Overgaard, K., Sereghy, T., and Boysen, G., Enhancing the efficacy of thrombolysis by AMPA receptor blockade with NBQX in a rat embolic stroke model, J. Neurol Sci., 119, 209, 1993.
85. Overgaard, K., Sereghy, T., Pedersen, H., and Boysen, G., Neuroprotection with NBQX and thrombolysis with rt-PA in rat embolic stroke, Neurol. Res., 15, 344, 1993.
86. Sheardown, M. J., Nielsen, E. O., Hansen, A. J., Jacobsen, P., and Honore, T., 2,3-Dihydroxy-6-nitro-7-sulfamoylbenzo(F)quinoxaline: a neuroprotectant for cerebral ischemia, Science, 247, 571, 1990.
87. Buchan, A. M., Li, H., Cho, S., and Pulsinelli, W. A., Blockade of the AMPA receptor prevents CA1 hippocampal injury following severe but transient forebrain ischemia in adult rats, Neurosci. Lett., 132, 255, 1991.
88. Kaiser, F., Hansen, A. J., Laursen, H., and Sheardown, M. J., NBQX protects against delayed cell death following complete forebrain ischemia in the rat, Mol. Neuropharmacol., 2, 219, 1992.
89. Nellgard, B. and Wieloch, T., Postischemic blockade of AMPA but not NMDA receptors mitigates neuronal damage in the rat brain following transient severe cerebral ischemia, J. Cereb. Blood Flow Metab., 12, 2, 1992.
90. LePeillet, E., Arvin, B., Moncada, C., and Meldrum, B., The non-NMDA antagonists, NBQX and GYKI52466, protect against cortical and striatal cell loss following transient global ischaemia in the rat, Brain Res., 511, 115, 1992.
91. Yatsugi, S., Kawasaki, S., Katoh, M., Takahashi, M., Koshiya, K., and Shimazu-Sasamata, M., Effects of a novel AMPA antagonist YM900 and other excitatory amino acid antagonists on the delayed neuronal death in the gerbil hippocampus, J. Cereb. Blood Flow Metab., 13, S635, 1993.
92. Sheardown, M. J., Suzdak, P. D., and Nordholm, L., AMPA, but not NMDA, receptor antagonism is neuroprotective in gerbil global ischemia, even when delayed 24 h, Eur. J. Pharmacol., 236, 347, 1993.
93. Li, H. and Buchan, A.M., Treatment with an AMPA antagonist 12 hours following severe normothermic forebrain ischemia prevents CA1 neuronal injury, J. Cereb. Blood Flow Metab., 13, 933, 1993.
94. Lippert, K., Welsch, M., and Krieglstein, J., Over-additive protective effect of dizocilpine and NBQX against neuronal damage, Eur. J. Pharmacol., 253, 207, 1994.
95. Bernert, H., Mathias, S., Löschmann, P.-A., and Turski, L., Traumatic brain injury prevented by the AMPA antagonist NBQX, Soc. Neurosci. Abstr., 20, 977, 1994.
96. Wrathall, J. R., Teng, Y. D., Choiniere, D., and Mundt, D. J., Evidence that local non-NMDA receptors contribute to functional deficits in contusive spinal cord injury, Brain Res., 586, 140, 1992.
97. Pierrefiche, O., Foutz, A. S., Champagnat, J., and Denavit-Saubrie, M., NMDA and non-NMDA receptors may play distinct roles in timing mechanisms and transmission in the feline respiratory network, J. Physiol., 474, 509, 1994.
98. Chen, K., Hernandez, Y. M., Dretchen, K. L., and Gillis, R. A., Intravenous NBQX inhibits spontaneously occurring sympathetic nerve activity and reduces blood pressure in cats, Eur. J. Pharmacol., 252, 155, 1994.
99. Buchan, A. M., Lesiuk, H., Barnes, K. A., Li, H., Huang, Z.-G., Smith, K. E., and Xue, D., AMPA antagonists: do they hold more promise for clinical stroke trials than NMDA antagonists? Stroke, 24, 1148, 1993.
100. McMaingle, J. E., Taveira DaSilva, A. M., Dretchen, K. L., and Gillis, R. A., Potentiation of MK-801-induced breathing impairment by 2,3-dihydroxy-6-nitro-7-sulfamoylbenzo(F)quinoxaline, Eur. J. Pharmacol., 252, 11, 1994.
101. McFarlane, C., Warner, D. S., Todd, M. M., and Nordhohn, L., AMPA receptor competitive antagonism reduces halothane MAC in rats, Anesthesiology, 77, 1165, 1992.
102. Dall, V., Orntoft, U., Schmidt, A., and Nordholm, L., Interaction of the competitive AMPA receptor antagonist NBQX with hexobarbital, Pharmacol. Biochem. Behav., 46, 7376, 1993.
103. Browne, S. E. and McCulloch, J., AMPA receptor antagonists and local cerebral glucose utilization in the rat, Brain Res., 641, 10, 1994.
104. McCulloch, J. and Iversen, L. L., Autoradiographic assessment of the effects of N-methyl-D-aspartate receptor antagonists in vivo, Neurochem. Res., 16, 951, 1991.
105. Swedberg, M. D. B., Jacobsen, P., and Honore, T., Discriminative effects of NBQX (2,3-dihydroxy-6-mtro-7-sulfamoyl-benzo(f)quinoxaline), Soc. Neurosci. Abstr., 17, 260, 1991.
106. Fisher, M., Jones, S., and Sacco, R. L., Prophylactic neuroprotection for cerebral ischemia, Stroke, 25, 1075, 1994.
107. Meldrum, B. S., Swan, J. H., Leach, M. J., Millan, M. H., Gwinn, R., Kadota, K., Graham, S. H., Chen, J., and Simon, R. P., Reduction of glutamate release and protection against ischemic brain damage by BW 1003C87, Brain Res., 593, 1, 1992.
108. Leach, M. J., Swan, J. H., Eisenthal, D., Dopson, M., and Nobbs, M., BW619C89, a glutamate release inhibitor, protects against focal cerebral ischemic damage, Stroke, 24, 1063, 1993.
109. Smith, S. E. and Meldrum, B. S., Cerebroprotective effect of lamotrigine after focal ischemia in rats, Stroke, 26, 117, 1995.
110. Malgorius, C., Bardot, F., Daniel, M., Pellis, F., Rataud, J., Uzan, J.-C., and Laduron, P. M., Riluzole, a novel antiglutamate, prevents memory loss and hippocampal neuronal damage in ischemic gerbils, J. Neurosci., 9, 3720, 1989.
111. Pratt, J., Rataud, J., Bardot, F., Roux, M., Blanchard, J.-C., Laduron, P. M., and Stutzmann, J. M., Neuroprotective actions of riluzole in rodent models of global and focal cerebral ischemia, Neurosci. Lett, 140, 225, 1992.
112. Lipton, S.A. and Rosenberg, P. A., Excitatory amino acids as a common pathway for neurologic disorders, N. Engl. J. Med., 330, 613, 1994.
113. Boxer, P. A., Cordon, J. J., Mann, M. E., Rodolosi, L. C., Vartanian, M. G., Rock, D. M., Taylor, C. P., and Marcoux, F. W., Comparison of phenytoin with noncompetitive N-methyl-D-aspartate antagonists in a model of focal brain ischemia in rat, Stroke, 21, III47, 1990.
114. Kinouchi, H., Imaizumi, S., Yoshimoto, T., and Motomiya, M., Phenytoin affects metabolism of free fatty acids and nucleotides in rat cerebral ischemia, Stroke, 21, 1326, 1990.
115. Qi, L. and Dong, W., Protective action of phenytoin on cerebral ischemia in rats, Chung-Hua i Hsueh Tsa Chih., 72, 420, 1992.
116. Hayakawa, T., Hamada, Y., Maihara, T., Hattori, H., and Mikawa, H., Phenytoin reduces neonatal hypoxic-ischemic brain damage in rats, Life Sci., 54, 387, 1994.
117. Rataud, J., Debarnot, F., Mary, V., Pratt, J., and Stutzmann, J.-M., Comparative study of voltage-sensitive sodium channel blockers in focal ischaemia and electric convulsions in rodents, Neurosci. Lett., 172, 19, 1994.
118. Rudolphi, K. A., Schubert, P., Parkinson, F. E., and Fredholm, B. B., Neuroprotective role of adenosine in cerebral ischemia, TIPS, 13, 439, 1992.
119. Lipton, S. A., Calcium channel antagonists in the prevention of neurotoxicity, Adv. Pharmacol., 22, 271, 1991.
120. Akopov, S. E., Calcium antagonists in cerebral ischemia: experimental basis and clinical experience, Drugs of Today, 30, 171, 1994.
121. Barone, F. C., Price, W. J., Jacobsen, P., Sheardown, M. J., and Feuerstein, G., Pharmacological profile of a novel neuronal calcium channel blocker includes reduced cerebral damage and neurological deficits in rat focal ischemia, Pharmacol. Bioch. Behav., 48, 77, 1994.
122. Schwarcz, R., Whetsell, W. O., and Mangano, R. M., Quinolinic acid: an endogenous metabolite that produces axon-sparing lesions in rat striatum, Science, 219, 316, 1983.
123. Do, K. Q., Herrling, P. L., Streit, P., Turski, W. A., and Cuenod, M., In vitro release and electrophysiological effects in situ of homocysteic acid, an endogenous N-methyl-(D)-aspartic acid agonist, in the mammalian striatum, J. Neurosci., 6, 2226, 1986.
124. Schwarcz, R., Speciale, C., and Turski, W. A., Kynurenines, glia and the pathogenesis of neurodegenerative disorders, in Parkinsonism and Ageing, Calne, D. B., Comi, G., Crippa, D., Horowski, R., and Trabucchi, M., Eds., Raven, New York, 1990, 97.
125. Beal, M. F., Mechanisms of excitotoxicity in neurologic diseases, FASEB J., 6, 3338, 1992.
126. Novelli, A., Reilly, J. A., Lysko, P. G., and Henneberry, R. C., Glutamate becomes neurotoxic via the N-methyl-D-aspartate receptor when intracellular energy levels are reduced, Brain Res., 451, 205, 1988.
127. Zeevalk, G. D. and Nicklas, W. J., Chemically induced hypoglycemia and anoxia: relationship to glutamate receptor-mediated toxicity in retina, J. Pharmacol. Exp. Ther., 253, 1285, 1990.
128. Zeevalk, G. D. and Nicklas, W. J., Mechanisms underlying initiation of excitotoxicity associated with metabolic inhibition, J. Pharmacol. Exp. Ther., 257, 870, 1991.
129. Urbańska, E., Ikonomidou, C., Sieklucka, M., and Turski, W. A., Aminooxyacetic acid produces excitotoxic lesions in the rat striatum, Soc. Neurosci. Abstr., 15, 764, 1989.
130. Urbańska, E., Ikonomidou, C., Sieklucka, M., and Turski, W. A., Aminooxyacetic acid produces excitotoxic lesions in the rat striatum, Synapse, 9, 129, 1991.
131. Turski, W. A., Urbanska, E., Sieklucka, M., and Ikonomidou, C., Quinolinate-like neurotoxicity produced by aminooxyacetic acid in rat striatum, Amino Acids, 2, 245, 1992.
132. Beal, M. F., Hyman, B. T., and Koroshetz, W., Do defects in mitochondrial energy metabolism underlie the pathology of neurodegenerative diseases? Trends Neurosci., 16, 125, 1993.
133. Wallace, D. C., Mitochondrial genetics: a paradigm for aging and degenerative diseases, Science, 256, 628, 1992.
134. + neurotoxicity by N-methyl-D-aspartate antagonists, Nature, 349, 414, 1991.
135. +, a metabolite of the neurotoxin MPTP, Life Sci., 36, 2503, 1985.
136. Beal, M. F., Swartz, K. J., Hyman, B. T., Storey, E., Finn, S. F., and Koroshetz, W., Aminooxyacetic acid results in excitotoxic lesions by a novel indirect mechanisms, J. Neurochem., 57, 1068, 1991.
137. McMaster, O. G., Du, F., French, E. D., and Schwarcz, R., Focal injection of aminooxyacetic acid produces seizures and lesions in rat hippocampus: evidence for mediation by NMDA receptors, Exp. Neurol, 113, 378, 1991.
138. Storey, E., Hyman, B. T., Jenkins, B., Brouillet, E., Miller, J. M., Rosen, B. R., and Beal, M. F., 1-Methyl-4-phenylpyridinium produces excitotoxic lesions in rat striatum as a result of impairment of oxidative metabolism, J. Neurochem., 58, 1975, 1992.
139. +) nigral toxicity in the rat by prior decortication or MK-801 treatment: a stereological estimate of neuronal loss, Neurobiol. Aging, 14, 295, 1993.
140. Turski, W. A., Aminooxyacetic acid produces excitotoxic lesions in the rat substantia nigra, Naunyn-Schmiedeberg's Arch. Pharmacol., 344, R67, 1991.
141. Beal, M. F., Brouillet, E., Jenkins, B., Ferrante, R. J., Kowall, N. W., Miller, J. M., Storey, E., Srivastava, R., Rosen, B. R., and Hyman, B. T., Neurochemical and histologic characterization of striatal excitotoxic lesions produced by the mitochondrial toxin 3-nitropropionic acid, J. Neurosci., 13, 4181, 1993.
142. Brouillet, E., Jenkins, B. G., Hyman, B. T., Ferrante, R. J., Kowall, N. W., Srivastava, R., Roy, D. S., Rosen, B. R., and Beal, M. F., Age-dependent vulnerability of the striatum to the mitochondrial toxin 3-nitropropionic acid, J. Neurochem., 60, 356, 1993.
143. Wüllner, U., Young, A. B., Penney, J. B., and Beal, M. F., 3-Nitropropionic acid toxicity in the striatum, J. Neurochem., 63, 1772, 1994.
144. Allen, C. N., Marino, J. L., and Meshul, C. K., 3-Nitropropionic acid (3-NPA)-induced axonal degeneration: a silver impregnation study, Neurodegeneration, 3, 225, 1994.
145. Beal, M. F., Brouillet, E., Jenkins, B., Henshaw, R., Rosen, B., and Hyman, B. T., Age-dependent striatal excitotoxic lesions produced by the endogenous mitochondrial inhibitor malonate, J. Neurochem., 61, 1147, 1993.
146. Greene, J. G., Porter, R. H. P., Eller, R. V., and Greenamyre, J. T., Inhibition of succinate dehydrogenase by malonic acid produces an "excitotoxic" lesion in rat striatum, J. Neurochem., 61, 1151, 1993.
147. Henshaw, R., Jenkins, B. G., Schulz, J. B., Ferrante, R. J., Kowall, B. R., and Beal, M. F., Malonate produces striatal lesions by indirect NMDA receptor activation, Brain Res., 647, 161, 1994.
148. Schulz, J. B., Henshaw, D. R., Jenkins, B. G., Ferrante, R. J., Kowall, N. W., and Beal, M. F., 3-Acetylpyridine produces age-dependent neuronal lesions by an excitotoxic and free radical mediated mechanism, J. Cereb. Blood Flow Metab., 14, 1024, 1994.
149. Nicotera, P., Bellomo, G., and Orrenius, S., Calcium-mediated mechanisms in chemically induced cell death, Ann. Rev. Pharmacol. Toxicol., 32, 449, 1992.
150. Rothman, S. M. and Olney, J. W., Excitotoxicity and the NMDA receptor, Trends Neurosci., 10, 299, 1987.
151. Torp, R., Arvin, B., LePeillet, E., Chapman, A. G., Ottersen, O. P., and Meldrum, B. S., Effect of ischemia and reperfusion on the extra- and intracellular distribution of glutamate, glutamine, aspartate and GABA in the rat hippocampus, with a note on the effect of the sodium channel blocker BW1003C87, Exp. Brain Res., 96, 365, 1993.
152. Turski, L. and Ikonomidou, C., Glutamate, energy metabolism and neuropathology: relevance to neurodegenerative disorders, in Parkinson's Disease and Extrapyramidal Disorders, Martignoni, E. and Nappi, G., Eds., Smith-Gordon, London, 1994, 15.
153. Corsini, G. U., Vaglini, F., Fornai, F., Saginario, A., and Zuddas, A., (+)MK 801 prevents dopaminergic perikarya damage in MPTP and acetaldehydetreated mice, Posters Neurosci., 1, 33, 1991.
154. Lange, K. W., Löschmann, P.-A., Sofic, E., Burg, M., Horowski, R., Kalveram, K. T., Wachtel, H., and Riederer, P., The competitive NMDA antagonist CPP protects substantia nigra from MPTP-induced degeneration in primates, Naunyn-Schmiedeberg's Arch. Pharmacol., 348, 569, 1993.
155. Lange, K. W., Youdim, M. B. H., and Riederer, P., Neurotoxicity and neuroprotection in Parkinson's disease, J. Neurol. Transm., S38, 27, 1992.
156. Mihatsch, W., Russ, H., and Przuntek, H., Intracerebroventricular administration of 1-methyl-4-phenylpyridinium ion in mice: effects of simultaneously administered nomifensine, deprenyl, and 1-t-butyl-4,4-diphenylpiperidine, J. Neurol. Transm., 71, 177, 1988.
157. Tabatabaei, A., Perry, T. L., Hansen, S., and Krieger, C., Partial effect of MK-801 on MPTP-induced reduction of striatal dopamine in mice, Neurosci. Lett., 141, 192, 1992.
158. Turski, L., Excitatory amino acid antagonists and Parkinson's disease, in Parkinson's Disease - from Basic Research and Early Diagnosis to Long-Term Treatment, Rinne, U. K., Nagatsu, T., and Horowski, R., Eds., Medicom, Bussum, 1991, 97.
159. Turski, L. and Melamed, E., Is there a role for excitatory amino acid antagonists? in Parkinson's Disease - Controversial Issues in Therapy, Marsden, C. D. and Oertel, W. H., Eds., Medicom, Bussum, 1993, 44.
160. Zuddas, A., Oberto, G., Vaglini, F., Fascetti, F., Fornai, F., and Corsini, G. U., MK 801 prevents MPTP-induced parkinsonism in primates, J. Neurochem., 59, 733, 1992.
161. + neurotoxicity by N-methyl-D-aspartate antagonist, Brain Res., 586, 203, 1992.
162. Heikkila, R. E., Nicklas, W. J., Vyas, I., and Duvoisin, R. C., Dopaminergic toxicity of rotenone and the 1-methyl-4-phenylpyridinium ion after their stereotaxic administration to rats: implication for the mechanism of 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine toxicity, Neurosci. Lett., 62, 389, 1985.
163. I0, Neurosci. Lett., 177, 58, 1994.
164. + seizures, Synapse, 10, 120, 1992.
165. Simpson, J. R. and Isacson, O., Mitochondrial impairment reduces the threshold for in vivo NMDA-mediated neuronal death in the striatum, Exp. Neurol., 121, 57, 1993.
166. Chan, P., Di Monte, D., and Langston, J. W., Effects of 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine (MPTP) on levels of glutamate and aspartate in the mouse brain, Brain Res., 647, 249, 1994.
167. Chan, P., Irwin, I., Di Monte, D., DeLanney, L. E., Sandy, M. S., and Langston, J. W., Selective decrease in glutamate levels in the nigrostriatal system of monkeys with parkinsonism, Ann. Neurol., 36, 314, 1994.
168. +-induced increase in striatal extracellular dopamine in rats in vivo, 5, 2157, 1994.
169. Otto, D. and Unsicker, K., Basic FGF reverses chemical and morphological deficits in the nigrostriatal system of MPTP-treated mice, J. Neurosci., 10, 1912, 1990.
170. Tomac, A., Lindquist, E., Lin, L.-F. H., Ögren, S. O., Young, D., Hoffer, B. J., and Olson, L., Protection and repair of the nigrostriatal dopaminergic system by GDNF in vivo, Nature, 373, 335, 1995.
171. Freese, A., Finklestein, S. P., and DiFiglia, M., Basic fibroblast growth factor protects striatal neurons in vitro from NMDA-receptor mediated excitotoxicity, Brain Res., 575, 351, 1993.
172. Nozaki, K., Finklestein, S. P., and Beal, M. F., Basic fibroblast growth factor protects against hypoxia-ischemia and NMDA neurotoxicity in neonatal rats, J. Cereb. Blood Flow Metab., 13, 221, 1993.
173. Nakata, N., Kato, H., and Kogure, K., Protective effects of basic fibroblast growth factor against hippocampal neuronal damage following cerebral ischemia in the gerbil, Brain Res., 605, 354, 1993.
174. Mattson, M. P., Zhang, Y., and Bose, S., Growth factors prevent mitochondrial dysfunction, loss of calcium homeostasis, and cell injury, but not ATP depletion in hippocampal neurons deprived of glucose, Exp. Neurol., 121, 1, 1993.
175. 1 ganglioside restores the dopamine content in striatum after chronic treatment with MPTP, Neuropharmacology, 25, 1075, 1986.
176. 1 ganglioside: in vivo and in vitro studies, Soc. Neurosci. Abstr., 19, 1052, 1993.
177. 1 ganglioside treatment, Science, 256, 843, 1992.
178. Lipartiti, M., Lazzaro, A., and Manev, H., Ganglioside derivative LIGA 20 reduces NMDA neurotoxicity in neonatal rat brain, Neuroreport, 3, 919 , 1992.
179. Kharlamov, A., Guidotti, A., Costa, E., Hayes, R., and Armstrong, D., Semisynthetic sphingolipids prevent protein kinase C translocation and neuronal damage in the perifocal area following a photochemically induced thrombotic brain cortical lesion, J. Neurosci., 13, 2483, 1993.
180. 1 reduces infarct volume after focal cerebral ischemia, Exp. Neurol., 125, 278, 1994.
181. 1, given orally after cortical thrombosis reduces infarct size and associated cognition deficit, Proc. Natl. Acad. Sci. U.S.A., 91, 6303, 1994.
182. Manev, H., Guidotti, A., and Costa, E., Protection by gangliosides against glutamate excitotoxicity, Adv. Lipid Res.,25, 269, 1993.
183. Manev, H., Favron, M., Vicini, S., Guidotti, A., and Costa, E., Glutamate-induced neuronal death in primary cultures of cerebellar granule cells: protection by synthetic derivatives of endogenous sphingolipids, J. Pharmacol. Exp. Ther., 252, 419, 1990.
184. Lenzi, G. L., Grigoletto, F., Gent, M., Roberts, R. S., Walker, M. D., Easton, J. D., Carolei, A., Dorsey, F. C., Rocca, W. A., Bruno, R., Patarnello, F., and Fieschi, C., Early treatment of stroke with monosialoganglioside GM-1. Efficacy and safety results of the early stroke trial, Stroke, 25, 1552, 1994.
185. Higashi, H. and Yamagata, T., Mechanism for ganglioside-mediated modulation of a calmodulin-dependent enzyme, J. Biol. Chem., 267, 9839, 1992.
186. Finiels-Marlier, F., Marini, A. M., Williams, P., and Paul, S. M., The N-methyl-D-aspartate antagonist MK-801 fails to protect dopaminergic neurons from 1-methyl-4-phenylpyridinium toxicity in vitro, J. Neurochem., 60, 1968, 1993.
187. +) in rat dissociated mesencephalic cultures, Brain Res., 597, 233, 1992.
188. Sawada, H., Shimohama, S., Kimura, J., Kawamura, T., Akaike, A., and Tamura, Y., Methylphenylpyridinium ion enhances glutamate-induced cytotoxicity against dopaminergic neurons in cultured rat mesencephalon, Neurosci. Res., 20, S63, 1994.
189. Ludolph, A. C.., Seelig, M.O., Ludolph, A., Novitt, P., Allen, C. N., Spencer, P. S., and Sabri, M. I., 3-Nitropropionic acid decreases cellular energy levels and causes neuronal degeneration in cortical explants, Neurode generation, 1, 21, 1992.
190. Spina, M. B., Squinto, S. P., Miller, J., Lindsay, R. M., and Hyman, C., Brain-derived neurotrophic factor protects dopamine neurons against 6-hydroxydopamine and N-methyl-4-phenylpyridinium ion toxicity: involvement of glutathione system, J. Neurochem., 59, 99, 1992.
191. Hibbs, J. B., Biological synthesis of nitric oxide from L-arginine, in Advances in Research on Neurodegeneration, II: Etiopathogenesis, Calne, D. B., Horowski, R., Mizuno, Y., Poewe, W. H., Riederer, P., and Youdim, M.B.H., Eds, Birkhäuser, Boston, 1993, 79.
192. Hibbs, J. B., Taintor, R. R., and Vavrin, Z., Macrophage cytotoxicity: role for L-arginine deaminase activity and imino nitrogen oxidation to nitrite, Science, 235, 473, 1987.
193. Drapier, J.-C. and Hibbs, J. B., Differentiation of murine macrophages to express nonspecific cytotoxicity for tumor cells results in L-arginine-dependent inhibition of mitochondrial iron-sulfur enzymes in the macrophage effect cells, J. Immunol., 140, 2829, 1988.
194. Garthwaite, J., Southam, E., and East, S. J., Glutamate receptors, nitric oxide, and cyclic GMP, in Excitatory Amino Acids and Second Messenger Systems, Teichberg, V. I. and Turski, L., Eds., Springer, Berlin, 1991, 87.
195. Dawson, V. L., Dawson, T. M., Bartley, D. A., Uhl, G. R., and Snyder, S. H., Mechanisms of nitric oxide-mediated neurotoxicity in primary brain cultures, J. Neurosci., 13, 2651, 1993.
196. Izumi, Y., Benz, A. M., Clifford, D. B., and Zorumski, C. F., Neurotoxic effects of sodium nitroprusside in rat hippocampal slices, Exp. Neurol., 121, 14, 1993.
197. Loiacono, R. E. and Beart, P. M., Hippocampal lesions induced by microinjection of the nitric oxide donor nitroprusside, Eur. J. Pharmacol., 216, 331, 1993.
198. Gross, P. M., Weaver, D. F., Bowers, R. J., Nag, S., Ho, L. T., Pang, J. J., and Espinosa, F. J., Neurotoxicity in conscious rats following intraventricular SNAP, a nitric oxide donor, Neuropharmacology, 33, 915, 1994.
199. Smith, R. P., Louis, C. A., Kruszyna, R., and Kruszyna, H., Acute neurotoxicity of sodium azide and nitric oxide, Fund. Appl. Toxicol., 17, 120, 1991.
200. Brouillet, E., Hyman, B. T., Jenkins, B. G., Henshaw, D. R., Schulz, J. B., Sodhi, P., Rosen, B. R., and Beal, M. F., Systemic and local administration of azide produces striatal lesions by an energy impairment-induced excitotoxic mechanism, Exp. Neurol., 129, 175, 1994.
201. Nowicki, J. P., Duval, H., Poignet, H., and Scatton, B., Nitric oxide mediates neuronal death after focal cerebral ischemia in the mouse, Eur. J. Pharmacol., 204, 339, 1991.
202. G-nitro-L-arginine protects against ischaemia-induced increases in nitric oxide and hippocampal neurodegeneration in the gerbil, Eur. J. Pharmacol., 260, 191, 1994.
203. Beal, M. F., Kowall, N. W, Ellison, D. W., Mazurek, M. F., Swartz, K. J., and Martin, J. B., Replication of the neurochemical characteristics of Huntington's disease by quinolinic acid, Nature, 321, 168, 1986.
204. Dawson, V. L., Dawson, T. M., London, E. D., Bredt, D. S., and Snyder, S. H., Nitric oxide mediates glutamate neurotoxicity in primary cortical cultures, Proc. Natl. Acad. Sci. U.S.A., 88, 6368, 1991.
205. Ikeda, J., Kashimura, J., Morita, I., and Murota, S., Endogenous nitric oxide inhibits glutamate-induced calcium influx exclusively in the NADPH diaphorase containing neurons, J. Cereb. Blood Flow Metab., 13, S39, 1993.
206. Lipton, S. A., Choi, Y.-B., Pan, Z.-H., Lei, S. Z., Chen, H.-S. V., Sucher, N. J., Loscalzo, J., Singel, D. J., and Stamler, J. S., A redox-based mechanism for the neuroprotective and neurodestructive effects of nitric oxide and related nitroso-compounds, Nature, 364, 626, 1993.
207. Manzoni, O. and Bockaert, J., Nitric oxide synthase activity endogenously modulates NMDA receptors, J. Neurochem., 61, 368, 1993.
208. +-induced cell injury in the striatum of rats, Br. J. Pharmacol., 111, 837, 1994.
209. Garthwaite, G. and Garthwaite, J., Cyclic AMP and cell death in rat cerebellar slices, Neuroscience, 26, 321, 1988.
210. Connop, B. P., Boegman, R. J., Jhmandas, K., and Beninger, R. J., Excitotoxic action of NMDA agonists on nigrostriatal dopaminergic neurons: modulation by inhibition of nitric oxide synthesis, Brain Res., 676, 124, 1995.
211. Manchester, K. S., Jensen, F. E., Warach, S., and Lipton, S. A., Chronic administration of nitroglycerin decreases cerebral infarct size, Neurology, 43, A365, 1993.
212. Zhang, F. and Iadecola, C., Reduction of focal cerebral ischemic damage by delayed treatment with nitric oxide donors, J. Cereb. Blood Flow Metab., 14, 574, 1994.
213. G-nitro-L-arginine enhances neuronal death following transient forebrain ischemia in gerbils, Neurosci. Lett., 146, 139, 1992.
214. Yamamoto, S., Golanov, E. V., Berger, S. B., and Reis, D. J., Inhibition of nitric oxide synthesis increases focal ischemic infarction in rat, J. Cereb. Blood Flow Metab., 12, 717, 1992.
215. Schulz, J. B., Matthews, R. T., Muqit, M. M. K., Browne, S. E., and Beal, M. F., Inhibition of neuronal nitric oxide synthase by 7-nitroindazole protects against MPTP induced neurotoxicity in mice, J. Neurochem., 64, 936 1995.
216. Schapira, A. H. V., Evidence for mitochondrial dysfunction in Parkinson's disease - a critical appraisal, Mov. Disord., 9, 125, 1994.
217. Schulz, J. B. and Beal, M. F., Mitochondrial dysfunction in movement disorders, Curr. Opinion Neurol., 7, 333, 1994.
218. Jenner, P., Schapira, A. H. V., and Marsden, C. D., New insights into the cause of Parkinson's disease, Neurology, 42, 2241, 1992.
219. Schapira, A. H. V., Mann, V. M., Cooper, J. M., Dexter, D., Daniel, S. E., Jenner, P., Clark, J. B., and Marsden, C. D., Mitochondrial complex I deficiency in Parkinson's disease, J. Neurochem., 55, 2142, 1990.
220. Parker, W. D., Boyson, S. J., and Parks, J. K., Abnormalities of the electron transport chain in idiopathic Parkinson's disease, Ann. Neurol., 26, 719, 1989.
221. Shoffner, J. M., Watts, R. L., Juncos, J. L., Torroni, A., and Wallace, D. C., Mitochondrial oxidative phosphorylation defects in Parkinson's disease, Ann. Neurol., 30, 332, 1991.
222. Barroso, N., Campos, Y., Huertas, R., Esteban, J., Molina, J. A., Alonso, A., Gutierrezrivas, E., and Arenas, J., Respiratory chain enzyme activities in lymphocytes from untreated patients with Parkinson's disease, Clin. Chem., 39, 667, 1993.
223. Haas, R. H., Nasirian, F., Ward, D., Nakano, K., Pay, M., Hill, R., and Shults, C. W., Low platelet mitochondrial complex I activity in untreated early Parkinson's disease, Neurology, 44, A178, 1994.
224. Parker, W. D., Boyson, S. J., Luder, A. S., and Parks, J. K., Evidence for a defect in NADH: ubiquinone oxidoreductase (complex I) in Huntington's disease, Neurology, 40, 1231, 1990.
225. Brennan, W. A., Bird, E. D., and Aprillo, V. R., Regional mitochondrial metabolism in Huntington's disease brain, J. Neurochem., 44, 1448, 1985.
226. Parker, W. D., Filley, C. M., and Parks, J. K., Cytochrome oxidase deficiency in Alzheimer's disease, Neurology, 40, 1302, 1990.
227. Simonian, N. A. and Hyman, B. T., Cytochrome oxidase is altered in the hippocampal formation in Alzheimer's disease, Neurology, 43, A251, 1993.
228. Parker, W. D., Mahr, N. J., Filley, C. M., Parks, J. K., Hughes, D., Young, D. A., and Cullum, C. M., Reduced platelet cytochrome c oxidase activity in Alzheimer's disease, Neurology, 44, 1086, 1994.
229. Parker, W. D., Parks, J., Filley, C. M., and Kleinschmidt-DeMasters, B. K., Electron transport chain defects in Alzheimer's disease brain, Neurology, 44, 1090, 1994.
230. Mutisya, E. M., Bowling, A. C., and Beal, M. F., Cortical cytochrome oxidase activity is reduced in Alzheimer's disease, J. Neurochem., 63, 2179, 1994.
231. Higgins, D. S. and Greenamyre, J. T., Dihydrorotenone binding in Alzheimer's disease: a preliminary study, Neurology, 43, A251, 1993.
232. Bowling, A. C., Mutisya, E. M., Walker, L. C., Price, D. L., Cork, L. C., and Beal, M. F., Age-dependent impairment of mitochondrial function in primate brain, J. Neurochem., 60, 1964, 1993.
233. Schöis, L., Reichmann, H., Langkafel, M., Kuhn, W., and Przuntek, H., Mitochondrial disorders in cerebellar ataxias, Mov. Disorders, 1, S44, 1992.
234. Schon, E. A., Mitochondrial disorders in muscle, Curr. Opinion Neurol. Neurosurg., 6, 19, 1993.
235. Brouillet, E. P., Shinobu, L., McGarvey, U., and Beal, M. F., Manganese injection into the rat striatum produces excitotoxic lesions by impairing energy metabolism, Exp. Neurol., 120, 89, 1993.
236. 10 and nicotinamide block striatal lesions produced by the mitochondrial toxin malonate, Ann. Neurol., 36, 882, 1994.
237. Greenamyre, J. T., Garcia-Osuna, M., and Greene, J. G., The endogenous cofactors, thioctic acid and dihydrolipoic acid, are neuroprotective against NMDA and malonic acid lesions of striatum, Neurosci. Lett., 171, 17, 1994.
238. Koroshetz, W. J., Jenkins, B., Rosen, B., and Beal, M. F., Ubiquinone lowers occipital lactate levels in patients with Huntington's disease, Neurology, 43, A334, 1993.
239. Rothstein, J. D., Jin, L., Dykes-Hoberg, M., and Kuncl, R. W., Chronic inhibition of glutamate uptake produces a model of slow neurotoxicity, Proc. Natl. Acad. Sci. U.S.A., 90, 6591, 1993.
240. Rothstein, J. D., Martin, L. J., and Kuncl, R. W., Decreased glutamate transport by the brain and spinal cord in amyotrophic lateral sclerosis, N. Engl. J. Med., 326, 1464, 1992.
241. Plaitakis, A., Constantakakis, E., and Smith, J., The neuroexcitotoxic amino acids glutamate and aspartate are altered in the spinal cord and brain in amyotrophic lateral sclerosis, Ann. Neurol., 24, 446, 1988.
242. Rothstein, J. D., Tsai, G., Kuncl, R., Clawson, L., Cornblath, D. R., Drachman, D. B., Pestronk, A., Stauch, B. L., and Coyle, J. T., Abnormal excitatory amino acid metabolism in amyotrophic lateral sclerosis, Ann. Neurol., 28, 18, 1990.
243. Prehn, J. H., Lippert, K., and Krieglstein, J., Are NMDA or AMPA/kainate receptor antagonists more efficacious in the delayed treatment of excitotoxic neuronal injury? Eur. J. Pharmacol., 292, 179, 1995.
244. Turski, L., Jacobsen, P., Honore, T., and Stephens, D. N., Relief of experimental spasticity and anxiolytic/ anticonvulsant actions of the α-amino-3-hydroxy-5-methyl-4-isoxazolepropionate antagonist 2,3-dihydroxy-6-mtro-7-sulfamoyl-benzo(F)quinoxaline, J. Pharmacol. Exp. Ther., 260, 742, 1992.
245. Vannucci, R. C., Experimental biology of cerebral hypoxia-ischemia: relation to perinatal brain damage, Pediatr. Res., 27, 317, 1990.
246. Edwards, M. S. B., Pitts, L. H., and Cogen, P. H., Trauma of the brain and spinal cord, in Child Neurology, Berg, B. O., Ed., Lippincott, Philadelphia, 1994, 155.
247. Miller, V. S., Pharmacologic management of neonatal cerebral ischemia and hemorrhage: old and new directions, J. Child Neurol., 8, 7, 1993.
248. Raju, T. N. K., Some animal models for the study of perinatal asphyxia, Biol. Neonat., 62, 202, 1992.
249. Ikonomidou, C., Qin, Y. Q., Labruyere, J., and Olney, J. W., Trauma causes glutamate-type cytopathology in infant rat brain, Soc. Neurosci. Abstr., 20, 1677, 1994.
250. Olney, J. W. and Ho, O. L., Brain damage in infant mice following oral intake of glutamate, aspartate and cysteine, Nature, 227, 609, 1970.
251. Olney, J. W., Glutamate-induced neuronal necrosis in the infant mouse hypothalamus: an electron microscopic study, J. Neuropathol. Exp. Neurol., 30, 75, 1971.
252. Olney, J. W., Sharpe, L. G., and Feigin, R. D., Glutamate-induced brain damage in infant primates, J. Neuropathol. Exp. Neurol., 31, 464, 1972.
253. Ikonomidou, C., Price, M. T., Mosinger, J. L., Friedrich, G., Labruyere, J., and Olney, J. W., Hypobaric-ischemic conditions produce glutamate-like cytopathology in infant rat brain, J. Neurosci., 9, 1693, 1989.
254. Andiné, P., Sandberg, M., Bagenholm, R., Lehmann, A., and Hagberg, H., Intra- and extracellular changes of amino acids in the cerebral cortex of the neonatal rat during hypoxic ischemia, Dev. Brain Res., 64, 115, 1991.
255. Silverstein, F. S., Naik, B., and Simpson, J., Hypoxia-ischemia stimulates hippocampal glutamate efflux in perinatal rat brain: an in vivo microdialysis study, Pediatr. Res., 30, 587, 1991.
256. Olney, J. W. and Ikonomidou, C., Excitotoxic mechanisms operative in youth and old age, in Neurobiology of the NMDA Receptor, Kozikowski, A., Ed., VCH, New York, 1991, 187.
257. Ikonomidou, C., Mosinger, J. L., Shahid Salles, K., Labruyere, J., and Olney, J. W., Sensitivity of the developing rat brain to hypobaric/ischemic damage parallels sensitivity to N-methyl-D-aspartate neurotoxicity, J. Neurosci., 9, 2809, 1989.
258. McDonald, J. W. and Johnston, M. V., Physiological and pathological roles of excitatory amino acids during central nervous system development, Brain Res. Rev., 15, 41, 1990.
259. Grafe, M. R., Developmental changes in the sensitivity of the neonatal rat brain to hypoxic/ischemic injury, Brain Res., 653, 161, 1994.
260. Ikonomidou, C., Labruyere, J., Benz, A., and Olney, J. W., Antagonistic pharmacology of glutamate toxicity in infant rat brain, Soc. Neurosci. Abstr., 15, 767, 1989.
261. Olney, J. W., Ikonomidou, C., Mosinger, J. L., and Friedrich, G., MK-801 prevents hypobaric-ischemic neuronal degeneration in infant rat brain, J. Neurosci., 9, 1701, 1989.
262. Hagberg, H., Diemer, N.-H., and Andiné, P., Hypoxic-ischemic brain damage in the newborn rat: effect of NMDA- and AMPA-receptor antagonists, Biol. Neonat., 62, 299, 1992.
263. Ikonomidou, C. and Olney, J. W., Developmental excitotoxicity for explaining neuropsychiatric disturbances, Neuropsychopharmacology, 10, 448S, 1994.
264. Ikonomidou, C., Qin, Y.-Q., Labruyere, J., Kirby, C., and Olney, J. W., Prevention of trauma-induced neurodegeneration in infant rat brain, Pediatric Res., 39, 1020, 1996.
265. Simon, R. P., Young, R. S. K., Stout, S., and Cheng, J., Inhibition of excitatory neurotransmission with kynurenate reduces brain edema in neonatal anoxia, Neurosci. Lett., 71, 361, 1986.
266. McDonald, J. W., Silverstein, F. S., and Johnston, M. V., MK-801 protects the neonatal brain from hypoxic-ischemic damage, Eur. J. Pharmacol., 140, 359, 1987.
267. Andine, P., Lehmann, A., Ellren, K., Wennberg, E., Kjellmer, I., Nielsen, T., and Hagberg, H., The excitatory amino acid antagonist kynurenic acid administered after hypoxic-ischemia in neonatal rats offers neuroprotection, Neurosci. Lett, 90, 208, 1988.
268. Ford, L. M., Sanberg, P. R., Norman, A. B., and Gogelson, M. H., MK-801 prevents hippocampal neurodegeneration in neonatal hypoxic-ischemic rats, Arch. Neurol., 46, 1090, 1989.
269. Silverstein, F. S., McDonald, J. W., Bommarito, M., and Johnston, M. V., Effects of hypoxia-ischemia and MK-801 treatment on the binding of a phencyclidine analogue in the developing rat brain, Stroke, 21, 310, 1990.
270. Hattori, H., Morin, A. M., Schwartz, P. H., Fujikawa, D. G., and Wasterlain, C. G., Posthypoxic treatment with MK-801 reduces hypoxic-ischemic damage in the neonatal rat, Neurology, 39, 713, 1989.
271. Wasterlain, C. G., Adams, L. M., Schwartz, P. H., Hattori, H., Sofia, R. D., and Wichmann, J. K., Posthypoxic treatment with felbamate is neuroprotective in a rat model of hypoxia-ischemia, Neurology, 43, 2303, 1993.
272. Wasterlain, C. G., Adams, L. M., Hattori, H., and Schwartz, P. H., Felbamate reduces hypoxic-ischemic brain damage in vivo, Eur. J. Pharmacol., 212, 275, 1992.
273. Nozaki, K. and Beal., M. F., Neuroprotective effects of L-kynurenine on hypoxia-ischemia and NMDA lesions in neonatal rats, J. Cereb. Blood Flow Metab., 12, 400, 1992.
274. Hamada, Y., Hayakawa, T., Hattori, H., and Mikawa, H., Inhibitor of nitric oxide synthesis reduces hypoxic-ischemic brain damage in the neonatal rat, Pediatr. Res., 35, 10, 1993.
275. G-nitro-L-arginine in focal stroke in the 7-day old rat, Eur. J. Pharmacol., 218, 197, 1992.
276. Hayakawa, T., Hamada, Y., Maihara, T., Hattori, H., and Mikawa, H., Phenytoin reduces neonatal hypoxic-ischemic brain damage in rats, Life Sci., 54, 387, 1994.
277. 1 reduces NMDA neurotoxicity in neonatal rat brain, Exp. Neurol., 113, 301, 1991.
278. Monyer, H., Burnashev, N., Laurie, D. J., Sakmann, B., and Seeburg, P., Developmental and regional expression in the rat brain and functional properties of four NMDA receptors, Neuron, 12, 529, 1994.
279. 2+ block of the N-methyl-D-aspartate receptor-mediated synaptic potentials in developing visual cortex, Proc. Natl. Acad. Sci. U.S.A., 90, 7114, 1993.
280. Farber, N. B., Price, M. T., Labruyere, J., Fuller, T. A., and Olney, J. W., Age dependency of NMDA antagonist neurotoxicity, Soc. Neurosci. Abstr., 18, 1148, 1992.
281. Holmes, G. L., Werner, S., Liu, Z., Carmant, L., and Mikati, M., Adverse effects of excitatory amino acid antagonists on the developing brain, Ann. Neurol., 36, 494, 1994.
282. Dall'olio, R., Facchinetti, F., Contestabile, A., and Gandolfi, O., Chronic neonatal blockade of N-methyl-D-aspartate receptor by CGP 39551 increases dopaminergic function in adult rat, Neuroscience, 63, 451, 1994.
283. Sica, A. L., Siddiqi, Z. A., and Pisana, F., The effects of N-methyl-D-aspartate antagonism on the inspiratory activities of developing animals, Dev. Brain Res., 65, 281, 1992.
284. Sica, A. L. and Siddiqi, Z. A., Reduction of baroreceptor-related sympathetic discharge during NMDA receptor antagonism, Brain Res., 665, 323, 1994.
285. Campociaro, P. and Coyle, J. T., Ontogenetic development of kainate neurotoxicity: correlates with glutamatergic innervation, Proc. Natl. Acad. Sci. U.S.A., 75, 2025, 1978.
286. Cavalheiro, E. A., de Feo, M. R., and Ricci, G. F., Intracortical and intrahippocampal injections of kainic acid in developing rats: an electrographic study, Electroencephalogr. Clin. Neurophysiol., 56, 480, 1983.
287. Albala, B. J., Moshe, S. L., and Okada, R., Kainic acid-induced seizures: a developmental study, Dev. Brain Res., 13, 139, 1984.
288. Ben-Ari, Y., Tremblay, E., Berger, M., and Nitecka, L., Kainic acid seizure syndrome and binding sites in developing rats, Dev. Brain Res., 14, 284, 1984.
289. Takemoto, T., Isolation and structural identification of naturally occurring excitatory amino acids, in Kainic acid as a Tool in Neurobiology, McGeer, E., Olney, J. W., and McGeer, P., Eds., Raven, New York, 1978, 1.
290. Pearl, T. M., Bedard, L., Kosatsky, T., Hockin, J. C., Todd, E. C. D., and Remis, R. S., An outbreak of toxic encephalopathy caused by eating mussels contaminated with domoic acid, N. Engl. J. Med., 322, 1775, 1990.
291. Teitelbaum, J. S., Zatorre, R. J., Carpenter, S., Gendron, D., Evans, A. C., Gjedde, A., and Cashman, N. R., Neurologic sequelae of domoic acid intoxication due to the ingestion of contaminated mussels, N. Engl. J. Med., 322, 1781, 1990.
292. Shuaib, A. and Boyle, C., Stroke in the elderly, Curr. Opinion Neurol., 7, 41, 1994.
293. Yao, H., Sadoshima, S., Ooboshi, H., Sato, Y., Uchimura, H., and Fujishima, M., Age-related vulnerability to cerebral ischemia in spontaneously hypertensive rats, Stroke, 22, 1414, 1991.
294. Topp, K. S., Faddis, B. T., and Vijayan, V. K., Trauma-induced proliferation of astrocytes in the brains of young and aged rats, Glia., 2, 201, 1989.
295. Wexler, B. C., Carotid artery ligation-induced cerebral ischemia in old, male, Sprague-Dawley rats, Age, 2, 39, 1979.
296. Hoffman, W. E., Pelligrino, D., Miletich, D. J., and Albrecht, R. F., Brain metabolic changes in young vs. aged rats during hypoxia, Stroke, 16, 860, 1985.
297. Baughman, V. L., Hoffman, W. E., Thomas, C., Miletich, D. J., and Albrecht, R. F., Neurologic outcome in aged rats after incomplete cerebral ischemia, Anesth. Analg., 69, 192, 1988.
298. Miquel, J., Economos, A. C., Fleming, J., and Johnson, J., Mitochondrial role in cell aging, Exp. Gerontal., 15, 575, 1980.
299. Ferrandiz, M. L., Martinez, M., De Juan, E., Diez, A., Bustos, G., and Miquel, J., Impairment of mitochondrial oxidative phosphorylation in the brain of aged mice, Brain Res., 644, 335, 1994.
300. Mecocci, P., MacGarvey, U., Kaufman, A. E., Koontz, D., Shoffner, J. M., Wallace, D. C., and Beal., M. F., Oxidative damage to mitochondrial DNA shows marked age-dependent increases in human brain, Ann. Neurol., 34, 609, 1993.
301. Mecocci, P., MacGarvey, U., and Beal, M. F., Oxidative damage to mitochondrial DNA is increased in Alzheimer's disease, Ann. Neurol., 36, 747, 1994.